Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment

Alzheimer's disease (AD) is an age‐associated neurodegenerative disorder, characterized by memory loss, retardation of thinking and reasoning, progressive cognitive impairment, and changes in personality and behaviors.1 AD is the most frequent cause of dementia, accounting for 60%–80% of all ca...

ver descrição completa

Detalhes bibliográficos
Autores: Mayo, Paloma, Pascual, Jorge, Crisman, Enrique, Domínguez, Cristina, López, Manuela G., León, Rafael
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2024
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositório:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/360459
Acesso em linha:http://hdl.handle.net/10261/360459
Access Level:Acceso aberto
Palavra-chave:Alzheimer's disease
drug targets combinations
multifactorial disease
multitarget‐directed ligands
multitarget drugs
polypharmacology drug
id ES_34f3a04f4e1eab5c767686daa5872c36
oai_identifier_str oai:digital.csic.es:10261/360459
network_acronym_str ES
network_name_str España
repository_id_str
spelling Innovative pathological network-based multitarget approaches for Alzheimer's disease treatmentMayo, PalomaPascual, JorgeCrisman, EnriqueDomínguez, CristinaLópez, Manuela G.León, RafaelAlzheimer's diseasedrug targets combinationsmultifactorial diseasemultitarget‐directed ligandsmultitarget drugspolypharmacology drugAlzheimer's disease (AD) is an age‐associated neurodegenerative disorder, characterized by memory loss, retardation of thinking and reasoning, progressive cognitive impairment, and changes in personality and behaviors.1 AD is the most frequent cause of dementia, accounting for 60%–80% of all cases. 2 In 2022, AD affected over 55 million people around the world being the seventh leading cause of mortality and morbidity, a figure that will increase to 152 million by 2050,3 with an estimation of 10 million new cases each year and a projected healthcare expenditure of around US $1.1 trillion in the United States. 4 AD incidence increases dramatically with age, being 5% of people aged 65–74 years, 13% of people aged 75–84 years, and 33% of people aged 85 years or older.5 Although several genetic predisposition factors have been described, only 5% of cases are familiar or early‐onset, while 95% of the cases are sporadic or late‐onset (LOAD). To date, the causes driving LOAD onset and development remain elusive; however, different pathological pathways have been implicated, including aberrant protein aggregation, mitochondrial dysfunction, OS, calcium ion (Ca2+ ) dyshomeostasis, chronic neuroinflammation, and autophagy failure, among others. The progressive increase in LOAD cases, together with the fact that there is still no effective treatment, highlights the urgent need to find effective drugshe authors are grateful to financial support from the Spanish Ministry of Health (Instituto de Salud Carlos III) (grant PI17/001700 and PI20/00433), Spanish Ministry of Science (grant PID2021‐123481OB‐I00, and Comunidad de Madrid (grant P2022/BMD‐7230‐CAM‐22) to RL. P. M. expresses thanks to UAM for the FPI fellowship. The authors acknowledge the support by the European COST Action CA20121: Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (BenBedPhar). Webpage: https://benbedphar. org/about-benbedphar/, and would also like to thank “Fundación Teófilo Hernando” for its continued support. The authors acknowledge the support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).Peer reviewedWiley-VCHMinisterio de Sanidad (España)Instituto de Salud Carlos IIIMinisterio de Ciencia, Innovación y Universidades (España)European CommissionComunidad de MadridInstituto Fundación Teófilo HernandoCSIC - Unidad de Recursos de Información Científica para la Investigación (URICI)Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202420242024info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/360459reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.1002/med.22045Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3604592026-05-22T06:33:51Z
dc.title.none.fl_str_mv Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment
title Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment
spellingShingle Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment
Mayo, Paloma
Alzheimer's disease
drug targets combinations
multifactorial disease
multitarget‐directed ligands
multitarget drugs
polypharmacology drug
title_short Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment
title_full Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment
title_fullStr Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment
title_full_unstemmed Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment
title_sort Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment
dc.creator.none.fl_str_mv Mayo, Paloma
Pascual, Jorge
Crisman, Enrique
Domínguez, Cristina
López, Manuela G.
León, Rafael
author Mayo, Paloma
author_facet Mayo, Paloma
Pascual, Jorge
Crisman, Enrique
Domínguez, Cristina
López, Manuela G.
León, Rafael
author_role author
author2 Pascual, Jorge
Crisman, Enrique
Domínguez, Cristina
López, Manuela G.
León, Rafael
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Sanidad (España)
Instituto de Salud Carlos III
Ministerio de Ciencia, Innovación y Universidades (España)
European Commission
Comunidad de Madrid
Instituto Fundación Teófilo Hernando
CSIC - Unidad de Recursos de Información Científica para la Investigación (URICI)
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Alzheimer's disease
drug targets combinations
multifactorial disease
multitarget‐directed ligands
multitarget drugs
polypharmacology drug
topic Alzheimer's disease
drug targets combinations
multifactorial disease
multitarget‐directed ligands
multitarget drugs
polypharmacology drug
description Alzheimer's disease (AD) is an age‐associated neurodegenerative disorder, characterized by memory loss, retardation of thinking and reasoning, progressive cognitive impairment, and changes in personality and behaviors.1 AD is the most frequent cause of dementia, accounting for 60%–80% of all cases. 2 In 2022, AD affected over 55 million people around the world being the seventh leading cause of mortality and morbidity, a figure that will increase to 152 million by 2050,3 with an estimation of 10 million new cases each year and a projected healthcare expenditure of around US $1.1 trillion in the United States. 4 AD incidence increases dramatically with age, being 5% of people aged 65–74 years, 13% of people aged 75–84 years, and 33% of people aged 85 years or older.5 Although several genetic predisposition factors have been described, only 5% of cases are familiar or early‐onset, while 95% of the cases are sporadic or late‐onset (LOAD). To date, the causes driving LOAD onset and development remain elusive; however, different pathological pathways have been implicated, including aberrant protein aggregation, mitochondrial dysfunction, OS, calcium ion (Ca2+ ) dyshomeostasis, chronic neuroinflammation, and autophagy failure, among others. The progressive increase in LOAD cases, together with the fact that there is still no effective treatment, highlights the urgent need to find effective drugs
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/360459
url http://hdl.handle.net/10261/360459
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.1002/med.22045
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Wiley-VCH
publisher.none.fl_str_mv Wiley-VCH
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405850231111680
score 15,812429

Registros relacionados